Skip to main content

Calu-3 Transfection Reagent (Lung Carcinoma Cells, HTB-55)

The Calu-3 cell line was derived from the carcinomatous lung tissue of a 25 year old Caucasian male suffering from adenocarcinoma. Before the cell line was established the patient had received therapy with bleomycin, cytoxan, and adriamycin. The tumorigenic, epithelial cells of the Calu-3 cell line are now used to produce a  transfection host model for various types of lung cancer as well as other biomedical research. The Calu-3 transfection reagents established by Altogen Biosystems allow an intracellular delivery of pDNA, mRNA and siRNA and the recombinant protein expression desired in certain research. 

 Calu-3 Transfection Reagent (Lung Carcinoma Cells, HTB-55)
Labels:

Popular posts from this blog

Xenograft Models and Calu-3 Resources from Altogen Biosystems

Altogen Biosystems is a global provider and custom research organization for genetic research. Biological services and other experiments include ELISA testing, cell transfection optimization, stable transfection of cells, RNAi testing and more. Dedicated to helping customers with state-of-the-art and specialized services, Altogen Biosystems strives to advance modern clinical discoveries. Visit the official xenograft catalogue for a Calu-3 xenograft model .
Post a Comment
Read more

Calu-3 Cells for Lung Cancer Drug Development

Lung cancer is one of the more prominent cancers known to the medical field, with non-small cell lung carcionma (NSCLC) being the most common. Calu-3 cells come from such a cancer, and are useful tools in medical research evaluating the effects of genetic modification on cell proliferation. With the proper reagents , transfected siRNA, DNA, and RNA sequences can affect cell functionality and lead to important results that inform preclinical testing and in vitro  effects of gene therapies and drugs.
Post a Comment
Read more